中国慢性乙型肝炎治疗的进展与挑战

单姗; 贾继东

doi:10.12449/JCH250202

中国慢性乙型肝炎治疗的进展与挑战

DOI: 10.12449/JCH250202

单姗,
贾继东^, ,

首都医科大学附属北京友谊医院肝病中心，消化健康全国重点实验室，国家消化系统疾病临床医学研究中心，北京 100050

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：单姗负责撰写论文；贾继东负责拟定写作思路，指导论文撰写并修改论文。

详细信息

通信作者:
贾继东， jia_jd@ccmu.edu.cn （ORCID： 0000-0002-4673-8890）

计量
- 文章访问数: 1808
- HTML全文浏览量: 94
- PDF下载量: 115
- 被引次数: 0
出版历程
- 收稿日期: 2025-01-03
- 录用日期: 2025-01-10
- 出版日期: 2025-02-25

Advances and challenges in the treatment of chronic hepatitis B in China

Shan SHAN,
Jidong JIA^{,
,}

Liver Research Center，Beijing Friendship Hospital，Capital Medical University；State Key Laboratory of Digestive Health；National Clinical Research Center for Digestive Diseases，Beijing 100050，China

More Information

Corresponding author: JIA Jidong， jia_jd@ccmu.edu.cn （ORCID： 0000-0002-4673-8890）

摘要

摘要: 我国自1992年开始实行了以新生儿普遍接种乙型肝炎疫苗为核心的综合预防策略，极大地降低了人群（特别是低年龄组人群）中乙型肝炎病毒表面抗原阳性率。抗病毒治疗不仅可以改善肝脏组织学，而且还可以减少肝硬化及门静脉高压相关并发症及肝细胞癌的发生风险，从而改善临床预后。随着临床指南不断更新以及一线抗病毒药物价格大幅下降，治疗的可及性和可负担性大幅提高。但由于我国人口基数大、既往乙型肝炎流行率高，现存乙型肝炎感染人数仍然众多，诊断率和治疗率仍然偏低，乙型肝炎相关肝硬化和肝癌人群死亡率仍较高。因此，应通过积极的社会动员并采取医防结合的策略，开展大规模检测和治疗慢性乙型肝炎，助力实现世界卫生组织提出的2030年消除病毒性肝炎公共卫生危害的目标。
- 乙型肝炎 /
- 预防 /
- 治疗学
Abstract: Since 1992， China has adopted a comprehensive strategy centered on universal infant hepatitis B vaccination. This approach has led to a significant reduction in the prevalence of hepatitis B surface antigen， particularly among younger age groups. Antiviral therapy not only improves the liver histology but also reduces the incidences of complications of cirrhosis and portal hypertension， as well as the risk of hepatocellular carcinoma. Clinical guidelines for the prevention and treatment of chronic hepatitis B have been periodically updated， and the prices of antiviral drugs have been substantially lowered， enhancing treatment accessibility and affordability. However， the HBV-related disease burden remains high in China due to its large population， the considerable number of individuals already chronically infected with HBV， and the low rates of diagnosis and treatment. To meet the global goal of eliminating viral hepatitis as a public health threat by 2030， large-scale testing and treatment of those already infected with HBV are critical.
- Hepatitis B /
- Prevention /
- Therapeutics

HTML全文

参考文献(30)

[1]	WHO. Global hepatitis report 2024: action for access in low- and middle-income countries[EB/OL].( 2024-04-09)[ 2025-01-03]. https://www.who.int/publications/i/item/9789240091672. https://www.who.int/publications/i/item/9789240091672
[2]	ZHENG H, WANG Y, WANG FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51: 101193. DOI: 10.1016/j.lanwpc.2024.101193.
[3]	XU XQ, WANG H, SHAN S, et al. Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: A CR-HepB-based real-world study[J]. Chin J Hepatol, 2023, 31( 7): 698- 704. DOI: 10.3760/cma.j.cn501113-20230518-00226. 徐小倩, 王皓, 单姗, 等. 中国慢性乙型肝炎临床特征和抗病毒治疗模式十年变迁: 基于CR-HepB的真实世界研究[J]. 中华肝脏病杂志, 2023, 31( 7): 698- 704. DOI: 10.3760/cma.j.cn501113-20230518-00226.
[4]	MENG TT, MIAO N, ZHENG H, et al. Self-awareness rate and its influencing factors of their infection status among hepatitis B surface antigen-positive persons aged 15-69 years in China[J]. Chin J Hepatol, 2022, 30( 5): 534- 540. DOI: 10.3760/cma.j.cn501113-20220303-00097. 孟彤彤, 缪宁, 郑徽, 等. 中国15～69岁乙型肝炎表面抗原阳性者对自身感染状态的知晓率及其影响因素[J]. 中华肝脏病杂志, 2022, 30( 5): 534- 540. DOI: 10.3760/cma.j.cn501113-20220303-00097.
[5]	COOKE GS, FLOWER B, CUNNINGHAM E, et al. Progress towards elimination of viral hepatitis: A lancet gastroenterology& hepatology commission update[J]. Lancet Gastroenterol Hepatol, 2024, 9( 4): 346- 365. DOI: 10.1016/S2468-1253(23)00321-7.
[6]	WANG XR, DU ZC, WANG YJ, et al. Impact and cost-effectiveness of biomedical interventions on adult hepatitis B elimination in China: A mathematical modelling study[J]. J Epidemiol Glob Health, 2023, 13( 3): 517- 527. DOI: 10.1007/s44197-023-00132-1.
[7]	TOY M, HUTTON D, JIA JD, et al. Costs and health impact of delayed implementation of a national hepatitis B treatment program in China[J]. J Glob Health, 2022, 12: 04043. DOI: 10.7189/jogh.12.04043.
[8]	SUN YM, ZHOU JL, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65( 5): 1438- 1450. DOI: 10.1002/hep.29009.
[9]	CHANG XJ, LV CH, WANG BQ, et al. The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis[J]. Hepatology, 2024, 79( 2): 425- 437. DOI: 10.1097/HEP.0000000000000563.
[10]	WANG BQ, ZHOU JL, WU XN, et al. Carvedilol plus NUC for patients with HBV-compensated cirrhosis under virological suppression: A randomized open-label trial[J]. Am J Gastroenterol, 2024, 119( 4): 700- 711. DOI: 10.14309/ajg.0000000000002569.
[11]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII- Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
[12]	SUN YM, CHEN W, CHEN SY, et al. Regression of liver fibrosis in patients on hepatitis B therapy is associated with decreased liver-related events[J]. Clin Gastroenterol Hepatol, 2024, 22( 3): 591- 601. e 3. DOI: 10.1016/j.cgh.2023.11.017.
[13]	WANG Q, ZHAO H, DENG Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77( 6): 1564- 1572. DOI: 10.1016/j.jhep.2022.07.037.
[14]	HE ZY, WANG BQ, WU XN, et al. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: A 5-year multi-center observational study comparing patients with ascites and bleeding[J]. Hepatol Int, 2023, 17( 6): 1368- 1377. DOI: 10.1007/s12072-023-10579-w.
[15]	KONG YY, SUN YM, ZHOU JL, et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Viral Hepat, 2019, 26( 5): 576- 585. DOI: 10.1111/jvh.13058.
[16]	WU SS, KONG YY, PIAO HX, et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis[J]. Liver Int, 2018, 38( 6): 1045- 1054. DOI: 10.1111/liv.13623.
[17]	WEN XJ, WU XN, SUN YM, et al. Long-term antiviral therapy is associated with changes in the profile of transcriptionally active HBV integration in the livers of patients with CHB[J]. J Med Virol, 2024, 96( 6): e29606. DOI: 10.1002/jmv.29606.
[18]	HAN BF, ZHENG RS, ZENG HM, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4( 1): 47- 53. DOI: 10.1016/j.jncc.2024.01.006.
[19]	QU CF, CHEN TY, FAN CS, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: A cluster randomized controlled trial[J]. PLoS Med, 2014, 11( 12): e1001774. DOI: 10.1371/journal.pmed.1001774.
[20]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Infec Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
[21]	WANG Y, WANG M, ZHANG GH, et al. Control of chronic hepatitis B in China: Perspective of diagnosis and treatment[J]. China CDC Wkly, 2020, 2( 31): 596- 600. DOI: 10.46234/ccdcw2020.159.
[22]	TANG M, HE JJ, CHEN MX, et al.“4+7” city drug volume-based purchasing and using pilot program in China and its impact[J]. Drug Discov Ther, 2019, 13( 6): 365- 369. DOI: 10.5582/DDT.2019.01093.
[23]	SU S, WONG WC, ZOU ZR, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: An economic evaluation[J]. Lancet Glob Health, 2022, 10( 2): e278- e287. DOI: 10.1016/S2214-109X(21)00517-9.
[24]	Society of Prevention and Control of Infectious Diseases of Chinese Preventive Medicine Association; Working Committee of Promoting the Elimination of Viral Hepatitis of Chinese Preventive Medicine Association. Expert recommendations on screening, testing and management for hepatitis B virus infection in adults[J]. J Clin Hepatol, 2024, 40( 8): 1543- 1550. DOI: 10.12449/JCH240807. 中华预防医学会感染性疾病防控分会, 中华预防医学会促进消除病毒性肝炎工作委员会. 成人乙型肝炎病毒感染筛查、检测及管理专家建议[J]. 临床肝胆病杂志, 2024, 40( 8): 1543- 1550. DOI: 10.12449/JCH240807.
[25]	Working Committee of Promoting the Elimination of Viral Hepatitis of Chinese Preventive Medicine Association; Society of Prevention and Control of Infectious Diseases of Chinese Preventive Medicine Association. Expert recommendations on hepatitis B vaccination in adults[J]. J Clin Hepatol, 2024, 40( 8): 1551- 1556. DOI: 10.12449/JCH240808. 中华预防医学会促进消除病毒性肝炎工作委员会, 中华预防医学会感染性疾病防控分会. 成人乙型肝炎疫苗接种专家建议[J]. 临床肝胆病杂志, 2024, 40( 8): 1551- 1556. DOI: 10.12449/JCH240808.
[26]	WANG BQ, SHAN S, KONG YY, et al. Comparison of the population covered by the 2024 version of the WHO’s hepatitis B prevention and treatment guidelines and the Chinese antiviral treatment guidelines[J]. Chin J Hepatol, 2024, 32( 6): 525- 531. DOI: 10.3760/cma.j.cn501113-20240421-00218. 王冰琼, 单姗, 孔媛媛, 等. 世界卫生组织2024年版乙型肝炎防治指南与中国指南抗病毒治疗覆盖人群的比较[J]. 中华肝脏病杂志, 2024, 32( 6): 525- 531. DOI: 10.3760/cma.j.cn501113-20240421-00218.
[27]	WONG GL. Updated guidelines for the prevention and management of chronic hepatitis B-World Health Organization 2024 compared with China 2022 HBV guidelines[J]. J Viral Hepat, 2024, 31( Suppl 2): 13- 22. DOI: 10.1111/jvh.14032.
[28]	ZHANG SH, WANG C, LIU B, et al. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: An economic evaluation[J]. Lancet Reg Health West Pac, 2023, 35: 100738. DOI: 10.1016/j.lanwpc.2023.100738.
[29]	YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: Trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 10): 589- 604. DOI: 10.1038/s41575-019-0186-y.
[30]	ZENG HM, CAO MM, XIA CF, et al. Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: A multicenter prospective study[J]. Nat Cancer, 2023, 4( 9): 1382- 1394. DOI: 10.1038/s43018-023-00618-8.